Compare UBFO & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UBFO | TNYA |
|---|---|---|
| Founded | 1987 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.7M | 178.5M |
| IPO Year | 2001 | 2021 |
| Metric | UBFO | TNYA |
|---|---|---|
| Price | $10.46 | $0.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.33 |
| AVG Volume (30 Days) | 257.4K | ★ 3.2M |
| Earning Date | 04-17-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.57% | N/A |
| EPS Growth | N/A | ★ 54.96 |
| EPS | ★ 0.70 | N/A |
| Revenue | ★ $2,954,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.01 | ★ N/A |
| Revenue Growth | ★ 1.23 | N/A |
| 52 Week Low | $8.11 | $0.36 |
| 52 Week High | $11.52 | $2.35 |
| Indicator | UBFO | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 55.01 | 58.67 |
| Support Level | $9.31 | $0.65 |
| Resistance Level | $10.53 | $0.82 |
| Average True Range (ATR) | 0.20 | 0.05 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 75.00 | 91.38 |
United Security Bancshares operates as the holding for United Security Bank. It provides commercial banking services to the business and professional community, and individuals located in Fresno, Madera, Santa Clara, and Kern Counties. It offers checking and savings accounts, deposits, mortgage loans, credit and debit cards, safe deposit boxes, automated teller machines, wire transfers, money market accounts, mobile banking, and wealth management services. The company's primary sources of revenue are interest income from loans and investment securities.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.